title: Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
abstract: Dyskinesia represents a debilitating complication of L-3,4-dihydroxyphenylalanine (L-dopa) therapy for Parkinson's disease. Such motor manifestations are attributed to pathological activity in the motor parts of basal ganglia. However, because consistent funneling of information takes place between the sensorimotor, limbic, and associative basal ganglia domains, we hypothesized that nonmotor domains play a role in these manifestations. Here we report the changes in 2-deoxyglucose (2-DG) accumulation in the sensorimotor, limbic, and associative domains of basal ganglia and thalamic nuclei of four groups of nonhuman primates: normal, parkinsonian, parkinsonian chronically treated with L-dopa without exhibiting dyskinesia, and parkinsonian chronically treated with L-dopa and exhibiting overt dyskinesia. Although nondyskinetic animals display a rather normalized metabolic activity, dyskinetic animals are distinguished by significant changes in 2-DG accumulation in limbic- and associative-related structures and not simply in sensorimotor-related ones, suggesting that dyskinesia is linked to a pathological processing of limbic and cognitive information. We propose that these metabolic changes reflect the underlying neural mechanisms of not simply motor dyskinesias but also affective, motivational, and cognitive disorders associated with long-term exposure to L-dopa.
authors.affiliation: Basal Gang, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5543, Université Victor Segalen-Bordeaux 2, 33076 Bordeaux Cedex, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Guigoni
authors.forename: Qin
authors.initials: Q
authors.lastname: Li
authors.forename: Incarnation
authors.initials: I
authors.lastname: Aubert
authors.forename: Sandra
authors.initials: S
authors.lastname: Dovero
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bioulac
authors.forename: Bertrand
authors.initials: B
authors.lastname: Bloch
authors.forename: Alan R
authors.initials: AR
authors.lastname: Crossman
authors.forename: Christian E
authors.initials: CE
authors.lastname: Gross
authors.forename: Erwan
authors.initials: E
authors.lastname: Bezard
mesh_terms: D000818:Animals; D001479:Basal Ganglia / Q000737:chemistry / Q000503:physiopathology*; D003847:Deoxyglucose / Q000493:pharmacokinetics; D004409:Dyskinesia, Drug-Induced / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D005917:Globus Pallidus / Q000737:chemistry / Q000503:physiopathology; D007980:Levodopa / Q000627:therapeutic use / Q000633:toxicity*; D008032:Limbic System / Q000737:chemistry / Q000503:physiopathology*; D008252:Macaca fascicularis; D009044:Motor Cortex / Q000737:chemistry / Q000503:physiopathology; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000503:physiopathology; D012686:Septal Nuclei / Q000737:chemistry / Q000503:physiopathology; D013003:Somatosensory Cortex / Q000737:chemistry / Q000503:physiopathology; D013378:Substantia Nigra / Q000737:chemistry / Q000503:physiopathology; D020531:Subthalamic Nucleus / Q000737:chemistry / Q000503:physiopathology
chemical_list: D007980:Levodopa; D003847:Deoxyglucose
references.citation: Brain Res. 1999 Apr 17;825(1-2):104-14
references.pmid: 10216178
references.citation: Mov Disord. 1999;14 Suppl 1:40-7
references.pmid: 10493402
references.citation: Neuropsychologia. 2000;38(5):596-612
references.pmid: 10689037
references.citation: J Neurosci. 2000 Mar 15;20(6):2369-82
references.pmid: 10704511
references.citation: Brain. 2001 Mar;124(Pt 3):546-57
references.pmid: 11222455
references.citation: FASEB J. 2001 Apr;15(6):1092-4
references.pmid: 11292678
references.citation: Nat Rev Neurosci. 2001 Aug;2(8):577-88
references.pmid: 11484001
references.citation: J Neurosci. 2001 Sep 1;21(17):6853-61
references.pmid: 11517273
references.citation: J Neurosci. 2002 Sep 15;22(18):8117-32
references.pmid: 12223566
references.citation: Amino Acids. 2002;23(1-3):105-9
references.pmid: 12373525
references.citation: Neuropsychologia. 2002;40(13):2257-67
references.pmid: 12417456
references.citation: Nat Med. 2003 Jun;9(6):762-7
references.pmid: 12740572
references.citation: J Neurosci. 2004 Apr 7;24(14):3554-62
references.pmid: 15071103
references.citation: Brain. 1992 Jun;115 ( Pt 3):809-24
references.pmid: 1628204
references.citation: Trends Neurosci. 1990 Jul;13(7):266-71
references.pmid: 1695401
references.citation: Neuroscience. 1989;32(1):213-26
references.pmid: 2586750
references.citation: J Neural Transm Suppl. 1988;27:117-22
references.pmid: 3042909
references.citation: Science. 1979 Aug 17;205(4407):723-5
references.pmid: 462184
references.citation: Trans Am Neurol Assoc. 1968;93:56-63
references.pmid: 4885744
references.citation: J Comp Neurol. 1984 Jan 10;222(2):265-300
references.pmid: 6365984
references.citation: Prog Neurobiol. 1980;14(2-3):69-97
references.pmid: 6999537
references.citation: Exp Brain Res. 1994;102(2):305-18
references.pmid: 7705508
references.citation: Brain Res Brain Res Rev. 1995 Jan;20(1):128-54
references.pmid: 7711765
references.citation: Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
references.pmid: 7711769
references.citation: J Comp Neurol. 1993 Mar 1;329(1):111-28
references.pmid: 8454722
references.citation: J Neurochem. 1977 May;28(5):897-916
references.pmid: 864466
references.citation: Mov Disord. 1995 Nov;10(6):731-40
references.pmid: 8749992
references.citation: Neuroimage. 1996 Oct;4(2):119-50
references.pmid: 9345504
references.citation: Arch Neurol. 1998 Oct;55(10):1313-9
references.pmid: 9779658